Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr. Mitra KazemiJahromi

Dr. Mitra KazemiJahromi

Department of Endocrinology, Hormozgan University of Medical Sciences, Bandarabbas, Iran

Title: The association between serum lipid profile and glycosylated hemoglobin in type 2 diabetic patients

Biography

Biography: Dr. Mitra KazemiJahromi

Abstract

Background: Patients with type II diabetes are at high risk of dyslipidemia, and subsequently, cardiovascular diseases. The present study investigates the relationship between glycosylated hemoglobin and lipid profile, and its effect as a predictive indicator of dyslipidemia in type II diabetes.

Method: The present cross-sectional study enrolled 802 patients with type II diabetes. Glycosylated hemoglobin was divided into two groups (<8% and ≥8%).GFR at two levels (>60% and ≤60%) was measured using two different techniques (EPI and MDRD). Then, the relationship of lipid profile with different levels of HbA1C and GFR was separately determined.

Results: In the present study, 74% of those with HbA1C≤8% and 71% of those with HbA1C>8% were female. Cholesterol, Triglyceride and LDL were significantly higher in patients with HbA1C>8% compared to those with HbA1C≤8 %( P value<0.005, 0.046 and 0.005, respectively). The relationship with HDL was not significant. Moreover, analysis of data at two levels of GFR showed a significant difference in patients with GFR≥60 only in terms of Triglyceride. This relationship was significant using both EPI and MDRD methods (P value=o.o11 and 0.017 respectively).

Conclusion: Glycosylated hemoglobin can be used as a predictor of dyslipidemia in patients with type II diabetes, and its subsequent diagnosis and treatment, and thus prevention of cardiovascular diseases.